# Claim-by-claim evidence table

Research cutoff: 18 September 2026. This records claims being examined, not established medical or legal findings. Source video: https://www.youtube.com/watch?v=Kprmb3CdUn4

| Claim / issue | Evidence classification | What the reviewed record supports |
|---|---|---|
| Sydney footage represents a Royal Commission | Advocacy, not an official Commission finding | Speakers call for a Commission. A campaign event is not equivalent to one being established. See event context in the article. |
| Vaccine-induced cancer is established | Overstated; causation not established | Case reports, hypotheses and observational associations require independent validation and suitable comparisons. NCI says a causal cancer/recurrence/progression link has not been demonstrated. |
| Heart tumour proves cancer-causing integration | Likely source identified; preprint; unsupported causal leap | Hulscher et al., Zenodo 22677693, reports PCR fragments in total tumour DNA. Section 2.8.1 explicitly says integration was not assessed. The December 2021 booster postdated September resection. Initial doses preceded diagnosis; their causal role is not established by timing. |
| Lymphoma PET progression after booster | Verified case report; causation unresolved | Goldman et al. (2021) concerns pre-existing AITL. Authors suspected acceleration but warned against generalisation. Do not misrepresent it as merely normal reactive nodes or as proof of broad cancer risk. |
| Boosters suppress everyone's cancer-fighting T cells | Real small study, overgeneralised | Benitez Fuentes et al. studied 36 solid-cancer patients: 24 increased, 11 decreased, one persistently negative spike-specific response. No demonstrated loss of antitumour control or causal relapse endpoint. |
| Vaccine DNA routinely integrates into human genomes and causes cancer | Not established | Aldén's liver-cancer-cell experiment did not establish integration in recipients. A 2025 bladder case explicitly claims integration, but requests validation and cannot establish causation. Finding fragments, establishing an insertion, and proving a cancer-driving effect are separate steps. |
| Turbo cancer is a new vaccine-specific disease | Not established diagnosis | Aggressive cancers are real; hyperprogression literature and some early-onset cancer increases predate rollout. The video's exact mortality chart was not reconstructed. |
| Korean study proves vaccine-caused cancer | Observational association, not causation | One-year insurance-data associations have methodological concerns. Publisher editor's notice is an investigation notice, not a retraction. |
| Recognised vaccine injuries (context) | Established adverse-event patterns | TGA recognises myocarditis/pericarditis with mRNA vaccines and TTS with AstraZeneca. Serious/fatal injuries have occurred; these do not prove the separate cancer claims. |
| McCann's individual injury descriptions prove causation in every named case | Testimony, not independently adjudicated here | Preserve the speaker's account without inventing medical records, court findings or personal details. |
| Class action awaiting dismissal ruling | July 2026 report supported; current outcome not conclusively verified | Lawyers Weekly reported Owens reserved decision. Earlier Katzmann pleading order is a different procedural event. No liability finding asserted. |
| Section 132G ceased after 30 June 2022 | Statutory sunset verified; blanket illegality inference unsupported | Subsection (2)(b) preserves other statutory/lawful routes. Actual later spending authority requires separate tracing. |
| PBAC first assessed/recommended COVID vaccine only in 2026 | Timeline requires correction | Official December 2025 document records recommendation after May 2025 consideration. Recommendation, implemented funding and TGA approval are different stages. |

## Primary source links and PDFs
- Cardiac preprint: https://zenodo.org/records/22677693 ; PDF: https://zenodo.org/records/22677693/files/Fatal%20Cardiac%20Sarcoma%20Following%20COVID-19%20Vaccination.pdf
- Goldman lymphoma case: https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2021.798095/full ; PDF: https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2021.798095/pdf
- Benitez Fuentes: https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.975980/full ; PDF: https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.975980/pdf
- Aldén cell study: https://pmc.ncbi.nlm.nih.gov/articles/PMC8946961/
- Bladder case publisher record: https://ijirms.in/index.php/ijirms/article/view/2130
- Korean observational study: https://doi.org/10.1186/s40364-025-00831-w
- Methodological critique: https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2026.1772406/full
- NCI: https://www.cancer.gov/about-cancer/coronavirus/covid-19-vaccines-people-with-cancer
- TGA safety reporting: https://www.tga.gov.au/news/covid-19-vaccine-safety-reports/covid-19-vaccine-safety-report-27-07-2023

This is a focused review, not an exhaustive systematic review. Unproven does not mean every hypothetical risk is impossible. No treatment or vaccination decision should be based on this table alone.